A policy approach to the development of molecular diagnostic tests.
Efficiently generating evidence of clinical utility is a major challenge for ensuring clinical adoption of valuable diagnostics. A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests.
Duke Clinical Research Institute, Duke University School of Medicine and the Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, North Carolina, USA. kevin.schulman@duke.edu
Kevin A
KA
Schulman
Sean R
SR
Tunis
D015415:Biomarkers / Q000032:analysis; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000191:economics* / Q000379:methods*; D057766:Policy; D012051:Reimbursement Mechanisms; D014481:United States
D015415:Biomarkers